Immune cell sub-study
Research type
Research Study
Full title
How does the peripheral immune system contribute to the outcome of aneurysmal subarachnoid haemorrhage (aSAH) and acute, spontaneous intracerebral haemorrhage (ICH)?
IRAS ID
251606
Contact name
Craig Smith
Contact email
Sponsor organisation
The University of Manchester
Clinicaltrials.gov Identifier
n/a, n/a
Duration of Study in the UK
4 years, 0 months, 31 days
Research summary
Why? This study will look at how our immune system effects recovery after brain haemorrhage (bleed in the brain).
Brain haemorrhage is the most severe type of stroke with a highest risk of death or long-term disability. Current treatments are aimed at reducing the risk of further bleeding and preventing further disability. However, infections can have a negative effect on recovery.
What? This study will look at immune system changes in patients after brain haemorrhage. We know from our previous studies that brain haemorrhage can cause changes to specific blood cells called monocytes but how and why this happens is not fully understood.We will collect blood samples on three occasions after brain haemorrhage to measure the function of blood cells called monocytes to assess if severity of haemorrhage affects monocyte function, how changes in monocyte function effects short and long-term recovery or increase the risk of infection.
By also recruiting a number of people who have not suffered a brain haemorrhage (controls), we will compare monocyte function of controls to that in patients.
Increasing our understanding of the role of monocytes and immune function after brain haemorrhage may lead to potential new treatments that improve outcome.Who? This study is being conducted as a sub-study to two clinical drug trials (SCIL and BLOC-ICH) and only patients who have given consent to participate in these trials can participate in this sub-study. The non-haemorrhage control participants will also be recruited from around Salford and Manchester via Salford Citizen Scientist advertisement.
Where? The expertise and technology to measure immune cell function is located at the University of Manchester. Therefore only patients who are recruited to both trials from Salford Royal NHS Foundation Trust can participate in this study.
How? The sub-study will commence in November, 2018 to coincide with the start of recruitment to the SCIL trial and will last for approximately 2 years.REC name
North West - Haydock Research Ethics Committee
REC reference
18/NW/0835
Date of REC Opinion
17 Dec 2018
REC opinion
Favourable Opinion